PA.Sig: A Cell Death Program-Based Prognostic Signature for Glioma

A 2026 study by Huaichao Zhang presents a pyroptosis–apoptosis–associated gene signature (PA.Sig) derived from transcriptomic and clinical data. The signature stratifies glioma patients into high- and low-risk groups with significantly different overall survival. It was constructed using data from TCGA-GBMLGG and external validation cohorts, with functional validation in glioma cell lines.

Use Cases

• Stratifying glioma patient prognosis based on a cell death-associated gene signature.
• Analyzing tumor immune microenvironment characteristics linked to inflammatory cell death programs.
• Investigating associations between cell death signatures, malignant cell states, and genomic alterations.
• Modeling therapeutic response and vulnerability based on coordinated cell death landscapes.

Strengths

• Signature validated across multiple cohorts, including TCGA-GBMLGG.
• Analysis integrates bulk transcriptomics, single-cell RNA sequencing, and in vitro functional validation.
• Dataset is openly available under a CC-BY-4.0 license.

Limitations

• The primary file is a 184.2 KB PDF, which likely contains summary results rather than the underlying raw or processed data tables.
• Column-level documentation and sample data are unavailable, making direct computational reuse difficult.
• Row count and specific data formats for the analyzed matrices are unknown.

Provenance

Source

Transcriptomic and clinical data from TCGA-GBMLGG and external validation cohorts.

Collection Method

Integrative survival modeling, genomic alteration profiling, pathway enrichment, and single-cell RNA sequencing analysis.

Freshness

Last updated 2026-05-21 04:39:03.